Analyst Price Targets — IMA
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 29, 2024 10:17 am | David Nierengarten | Wedbush | $1.33 | $1.64 | Benzinga | This American Airlines Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday |
| May 29, 2024 7:22 am | David Nierengarten | Wedbush | $2.00 | $1.33 | TheFly | iKena Oncology downgraded to Neutral from Outperform at Wedbush |
Latest News for IMA
SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- ImageneBio, Inc. (Nasdaq: IMA, “Imagene,” or the “Company”), today announced management will participate in a fireside chat and hold one-on-one meetings at the 2026 Leerink Global Healthcare Conference taking place March 8-11 in Miami, Florida.
BML Capital Management LLC purchased a new position in ImageneBio, Inc. (NASDAQ: IMA) in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 182,509 shares of the company's stock, valued at approximately $1,487,000. ImageneBio makes up 1.1% of
Brings 20+ years of clinical development experience in autoimmune and inflammatory diseases, including OX40/OX40L program leadership Will build and lead Imagene's clinical organization and drive completion of the Phase 2b ADAPTIVE trial in atopic dermatitis Will expand Phase 2b trial footprint with planned international sites including in the UK and Europe SAN DIEGO, Feb. 10, 2026 (GLOBE NEWSWIRE) -- ImageneBio,…
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IMA.
U.S. House Trading
No House trades found for IMA.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.